Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
- Proceeds will fund continued development of IMVT-1401 in multiple indications
NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune…
